Drug profile · INN
flecainide acetate
FLECAINIDE ACETATE
flecainide acetate (FLECAINIDE ACETATE) is a sodium channel protein type v alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — flecainide acetate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
flecainide acetate (FLECAINIDE ACETATE) is a sodium channel protein type v alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel protein type V alpha subunit blocker
Primary target: Sodium channel protein type 5 subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is flecainide acetate?
flecainide acetate (FLECAINIDE ACETATE) is a sodium channel protein type v alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for flecainide acetate?
FLECAINIDE ACETATE is a marketed brand name for flecainide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of flecainide acetate?
flecainide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.